Subscribe to stay informed!
Devon-based Zynerba is set to be acquired by Harmony Biosciences Holdings in a $2 million deal, writes John George for the Philadelphia Business Journal…
Zynerba Pharmaceuticals, a clinical-stage pharmaceutical company based in Devon, is testing a CBD gel to help treat autism, writes Queen Muse for Philadelphia magazine…
Devon’s Zynerba Pharmaceuticals, which develops synthetic cannabinoid therapies, is focusing on several rare and near-rare neurological and psychiatric disorders that have unmet medical…
For Devon’s Zynerba Pharmaceuticals, the switch to a smaller patch for pain treatment using a synthetic cannabinoid has bumped back the company’s target…
It has been a good week for Zynerba Pharmaceuticals, as the Devon based company received very positive results from the first phase of testing on…
Zynerba Pharmaceuticals is still experiencing a rollercoaster ride on the NASDAQ under the ticker ZYNE, since launching its more than fully subscribed Initial Public Offering…
A synthetic medical marijuana pioneer recently transplanted in Devon is experiencing an exciting high this week as it prepares to go public with 10 years…
Richard A. Baron is now vice president and chief financial officer at Zynerba Pharmaceuticals, Inc. of Radnor, a specialty pharmaceutical company that has invested $13…
Before we send you to this site, please subscribe to our daily newsletter.